EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Factors affecting response and resistance to venetoclax in acute myeloid leukemia

Michael D Diamantidis

Frontiers in Oncology · 15.09.2025 · 15

DOI: 10.3389/fonc.2025.1577908 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 15.09.2025. Verfasst von Michael D Diamantidis. Beteiligte Einrichtung: Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, Larissa, Greece. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of the BCL2 inhibitor venetoclax in combination with hypomethylating agents (HMA) is a revolution for the treatment of frail and elderly acute myeloid leukemia (AML) patients. This effective treatment strategy is increasingly more and more applicable for other subsets of AML patients and is currently being tested in numerous clinical trials in combination with other drugs in all treatment lines. In particular, venetoclax combinations can also serve as a definitive therapy or as an effective bridge to allogeneic hematopoietic stem cell transplantation (HSCT). However, the factors affecting response to venetoclax in the abovementioned AML patients are not completely clear and understood until today. The aim of this review is to describe the molecular and clinical patterns of response and durable remission of venetoclax-based combinations in AML patients. Hence, mutations in IDH1, IDH2, ASXL1, NPM1, DDX41, chromatin-cohesin complex and splicing-factor genes predict superior response to venetoclax, while inferior response to the drug has been observed for FLT3-ITD, KRAS, NRAS and TP53 gene mutations. Intriguingly, the achievement of measurable residual disease (MRD) negativity in the first four cycles of venetoclax administration characterizes a subgroup of NPM1-mutated AML patients with a more favorable outcome. Even though focus will be given on factors influencing response to the drug in this review, the main mechanisms of resistance to venetoclax in AML patients will also be discussed.

Schlagwörter

Stichwörter der Autor:innen

BCL2 (B-cell lymphoma 2) inhibitionMCL1 (myeloid cell leukemia sequence 1) overexpressionacute myeloid leukemia (AML)azacitidine (AZA)hypomethylating agents (HMAs)resistanceresponsevenetoclax (VEN)

Autor:innen und Institutionen

  • Thalassemia and Sickle Cell Disease Unit, Department of Hematology, General Hospital of Larissa, Larissa, Greece.

Zitieren

APA

Diamantidis, M. D. (2025). Factors affecting response and resistance to venetoclax in acute myeloid leukemia. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1577908

Vancouver

Diamantidis MD. Factors affecting response and resistance to venetoclax in acute myeloid leukemia. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1577908

BibTeX
@article{Diamantidis2025,
  author = {Diamantidis, Michael D},
  title = {Factors affecting response and resistance to venetoclax in acute myeloid leukemia},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1577908}
}
Kostenlos starten →